Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1129402

registered interest
date	03/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the Government’s decision to not support the World Health Assembly's resolution on greater transparency for drug pricing on the affordability of medicines in the UK.
tabling member constituency	Bristol East
tabling member printed	Kerry McCarthy
uin	259098
answer	answer is ministerial correction date of answer 06/06/2019 answer text <p>The United Kingdom participates in various transparency initiatives, including the European Integrated Price Information Database, the World Health Organization’s Pharmaceutical Pricing Reimbursement Information Network, and the Global Fund Price and Quality Database. However, the UK has a long-established and globally-recognised track record of assessing the price of new, innovative medicines according to their clinical value, rather than pricing by their development costs or international reference prices. We believe that is the right approach: ensuring the development of the best medicines in areas of high unmet need are rewarded. The Government could not, therefore, agree to a resolution which had the potential to increase medicines prices and reduce patient access, by reducing the ability of the NHS to undertake commercial negotiations with pharmaceutical companies on the price of new medicines. The approach taken by the National Health Service has meant we were the first country in Europe to offer innovative CAR-T therapies, alongside many other new medicines.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 06/06/2019 15:58:52 answering member 4455 label Biography information for Seema Kennedy
tabling member	1491 label Biography information for Kerry McCarthy

1127201

registered interest
date	16/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the ongoing negotiations between the NHS and Vertex pharmaceuticals on the price of cystic fibrosis drug Orkambi, if he will set out the priorities for the UK's delegation to the World Health Assembly, 21-26 May 2019; and if they will support the Italian Government's proposed resolution to improve the transparency of markets for drugs, vaccines and other health-related technologies to strengthen states positions when negotiating drug prices with industry.
tabling member constituency	Sheffield, Brightside and Hillsborough
tabling member printed	Gill Furniss
uin	255358
answer	answer is ministerial correction date of answer 21/05/2019 answer text <p>The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices. It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the National Health Service. The Government fully supports the approach the National Institute for Health and Care Excellence and NHS England are adopting in the ongoing negotiations with Vertex Pharmaceuticals on access to their portfolio of cystic fibrosis medicines.</p><p> </p><p>The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 21/05/2019 16:22:48 answering member 4455 label Biography information for Seema Kennedy
tabling member	4571 label Biography information for Gill Furniss

1127214

registered interest
date	16/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the draft resolution for consideration by the World Health Assembly in May 2019 on improving the transparency of markets for medicines, vaccines and other health-related technologies, if the Government will withdraw its support for suggested amendments to remove every mention of high prices.
tabling member constituency	Liverpool, Walton
tabling member printed	Dan Carden
uin	255380
answer	answer is ministerial correction date of answer 21/05/2019 answer text <p>The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.</p><p> </p><p>The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 255381 255382 question first answered 21/05/2019 16:12:54 answering member 4455 label Biography information for Seema Kennedy
tabling member	4651 label Biography information for Dan Carden

1127215

registered interest
date	16/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the draft resolution for consideration by the World Health Assembly in May 2019 on improving the transparency of markets for medicines, vaccines and other health-related technologies, if the Government will take steps to help ensure that the recommendation to member states calls for mandatory rather than voluntary measures.
tabling member constituency	Liverpool, Walton
tabling member printed	Dan Carden
uin	255381
answer	answer is ministerial correction date of answer 21/05/2019 answer text <p>The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.</p><p> </p><p>The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 255380 255382 question first answered 21/05/2019 16:12:54 answering member 4455 label Biography information for Seema Kennedy
tabling member	4651 label Biography information for Dan Carden

1127216

registered interest
date	16/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if the Government will support the draft resolution for consideration by the World Health Assembly in May 2019 on improving the transparency of markets for medicines, vaccines and other health-related technologies.
tabling member constituency	Liverpool, Walton
tabling member printed	Dan Carden
uin	255382
answer	answer is ministerial correction date of answer 21/05/2019 answer text <p>The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.</p><p> </p><p>The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 255380 255381 question first answered 21/05/2019 16:12:54 answering member 4455 label Biography information for Seema Kennedy
tabling member	4651 label Biography information for Dan Carden